1580 related articles for article (PubMed ID: 17334511)
21. Augmentation of U46619 induced human platelet aggregation by aspirin.
Kim JM; Koo YK; Jin J; Lee YY; Park S; Yun-Choi HS
Platelets; 2009 Mar; 20(2):111-9. PubMed ID: 19235053
[TBL] [Abstract][Full Text] [Related]
22. Comparison of VASP-phosphorylation assay to light-transmission aggregometry in assessing inhibition of the platelet ADP P2Y12 receptor.
Pampuch A; Cerletti C; de Gaetano G
Thromb Haemost; 2006 Dec; 96(6):767-73. PubMed ID: 17139371
[TBL] [Abstract][Full Text] [Related]
23. Effects of a novel platelet nitric oxide donor (LA816), aspirin, clopidogrel, and combined therapy in inhibiting flow- and lesion-dependent thrombosis in the porcine ex vivo model.
Vilahur G; Segalés E; Salas E; Badimon L
Circulation; 2004 Sep; 110(12):1686-93. PubMed ID: 15381660
[TBL] [Abstract][Full Text] [Related]
24. Potentiation of platelet aggregation by heparin in human whole blood is attenuated by P2Y12 and P2Y1 antagonists but not aspirin.
Storey RF; May JA; Heptinstall S
Thromb Res; 2005; 115(4):301-7. PubMed ID: 15668190
[TBL] [Abstract][Full Text] [Related]
25. Anti-thrombotic effects and bleeding risk of AJvW-2, a monoclonal antibody against human von Willebrand factor.
Kageyama S; Yamamoto H; Nagano M; Arisaka H; Kayahara T; Yoshimoto R
Br J Pharmacol; 1997 Sep; 122(1):165-71. PubMed ID: 9298543
[TBL] [Abstract][Full Text] [Related]
26. The effect of P2Y-mediated platelet activation on the release of VEGF and endostatin from platelets.
Bambace NM; Levis JE; Holmes CE
Platelets; 2010; 21(2):85-93. PubMed ID: 20063989
[TBL] [Abstract][Full Text] [Related]
27. The active metabolite of prasugrel effectively blocks the platelet P2Y12 receptor and inhibits procoagulant and pro-inflammatory platelet responses.
Judge HM; Buckland RJ; Sugidachi A; Jakubowski JA; Storey RF
Platelets; 2008 Mar; 19(2):125-33. PubMed ID: 18297550
[TBL] [Abstract][Full Text] [Related]
28. Analysis of platelet alpha2-adrenergic receptor activity in stable coronary artery disease patients on dual antiplatelet therapy.
Béres BJ; Tóth-Zsámboki E; Vargová K; László A; Masszi T; Kerecsen G; Préda I; Kiss RG
Thromb Haemost; 2008 Nov; 100(5):829-38. PubMed ID: 18989527
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of ADP-induced P-selectin expression and platelet-leukocyte conjugate formation by clopidogrel and the P2Y12 receptor antagonist AR-C69931MX but not aspirin.
Storey RF; Judge HM; Wilcox RG; Heptinstall S
Thromb Haemost; 2002 Sep; 88(3):488-94. PubMed ID: 12353080
[TBL] [Abstract][Full Text] [Related]
30. Open multicentre study of the P2T receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes.
Storey RF; Oldroyd KG; Wilcox RG
Thromb Haemost; 2001 Mar; 85(3):401-7. PubMed ID: 11307804
[TBL] [Abstract][Full Text] [Related]
31. Acyl derivatives of coenzyme A inhibit platelet function via antagonism at P2Y1 and P2Y12 receptors: a new finding that may influence the design of anti-thrombotic agents.
Manolopoulos P; Glenn JR; Fox SC; May JA; Dovlatova NL; Tang SW; Thomas NR; Ralevic V; Heptinstall S
Platelets; 2008 Mar; 19(2):134-45. PubMed ID: 18297551
[TBL] [Abstract][Full Text] [Related]
32. Recombinant GPVI-Fc added to single or dual antiplatelet therapy in vitro prevents plaque-induced platelet thrombus formation.
Mojica Muñoz AK; Jamasbi J; Uhland K; Degen H; Münch G; Ungerer M; Brandl R; Megens R; Weber C; Lorenz R; Siess W
Thromb Haemost; 2017 Aug; 117(8):1651-1659. PubMed ID: 28569920
[TBL] [Abstract][Full Text] [Related]
33. P2Y₁₂ and EP3 antagonists promote the inhibitory effects of natural modulators of platelet aggregation that act via cAMP.
Iyú D; Glenn JR; White AE; Fox SC; Dovlatova N; Heptinstall S
Platelets; 2011; 22(7):504-15. PubMed ID: 21591981
[TBL] [Abstract][Full Text] [Related]
34. Detection of P2Y(14) protein in platelets and investigation of the role of P2Y(14) in platelet function in comparison with the EP(3) receptor.
Dovlatova N; Wijeyeratne YD; Fox SC; Manolopoulos P; Johnson AJ; White AE; Latif ML; Ralevic V; Heptinstall S
Thromb Haemost; 2008 Aug; 100(2):261-70. PubMed ID: 18690346
[TBL] [Abstract][Full Text] [Related]
35. The active metabolite of prasugrel inhibits ADP-stimulated thrombo-inflammatory markers of platelet activation: Influence of other blood cells, calcium, and aspirin.
Frelinger AL; Jakubowski JA; Li Y; Barnard MR; Fox ML; Linden MD; Sugidachi A; Winters KJ; Furman MI; Michelson AD
Thromb Haemost; 2007 Jul; 98(1):192-200. PubMed ID: 17598013
[TBL] [Abstract][Full Text] [Related]
36. A microchip flow-chamber system for quantitative assessment of the platelet thrombus formation process.
Hosokawa K; Ohnishi T; Fukasawa M; Kondo T; Sameshima H; Koide T; Tanaka KA; Maruyama I
Microvasc Res; 2012 Mar; 83(2):154-61. PubMed ID: 22166857
[TBL] [Abstract][Full Text] [Related]
37. Adenosine diphosphate receptors on blood platelets: potential new targets for antiplatelet therapy.
Rozalski M; Nocun M; Watala C
Acta Biochim Pol; 2005; 52(2):411-5. PubMed ID: 15912207
[TBL] [Abstract][Full Text] [Related]
38. Effects of inhibition of P2Y(1) and P2Y(12) on whole blood clotting, coagulum elasticity and fibrinolysis resistance studied with free oscillation rheometry.
Ramström S; Rånby M; Lindahl TL
Thromb Res; 2003 Mar; 109(5-6):315-22. PubMed ID: 12818256
[TBL] [Abstract][Full Text] [Related]
39. Reduced effect of aspirin on thrombus formation at high shear and disturbed laminar blood flow.
Barstad RM; Orvim U; Hamers MJ; Tjønnfjord GE; Brosstad FR; Sakariassen KS
Thromb Haemost; 1996 May; 75(5):827-32. PubMed ID: 8725731
[TBL] [Abstract][Full Text] [Related]
40. Antagonists of the platelet P2T receptor: a novel approach to antithrombotic therapy.
Ingall AH; Dixon J; Bailey A; Coombs ME; Cox D; McInally JI; Hunt SF; Kindon ND; Teobald BJ; Willis PA; Humphries RG; Leff P; Clegg JA; Smith JA; Tomlinson W
J Med Chem; 1999 Jan; 42(2):213-20. PubMed ID: 9925726
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
